Shivshankar Gunjegaonkar

Dr. Shivshankar Gunjegaonkar

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2019 in Plant Signaling & Behavior
Verified
Journal Article
Closed access
SGShivshankar Gunjegaonkar
Shivshankar Gunjegaonkar
TST.S. Shanmugarajan
T.S. Shanmugarajan
Plant stress hormones (Phytohormones/PTH) are abundantly present in numerous vascular plants. Several classes of plant stress hormones like auxins (AU) & gibberellins (GA), cytokinins (CK), abscisic acid (ABA), ethylene (ET), salicylic acid (SA), jasmonates (JA), brassinosteroids (BR) and strigolactones are synthesized within specialized plant cells. Among them, jasmonate are prominent class of stress hormones involved in survival of plants in stressful conditions. Methyl jasmonate (MeJA) is ester of jasmonic acid is extensively studied for its potential clinical benefits. MeJA is used as an effective antimicrobial agent, food preservative, antioxidant in food and agricultural sectors. The clinical benefits of MeJA have been related to their prominent interactions with inflammatory NF-κB pathways, inhibition of enzymes, gene expression for synthesis of inflammatory mediators, signaling molecules, oxidative stress and modulation of pain perception/nociceptive responses. The objective of the present review is to provide an cohesive relation of MeJA in inflammation with reference to past and recent in-vivo and in-vitro investigations in broad perspectives.

29 November 2018 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
SGShivshankar Gunjegaonkar
Shivshankar Gunjegaonkar
TST. S. Shanmugarajan
T. S. Shanmugarajan

10 November 2020 in Heliyon
Verified
Journal Article
Open access
PDF file
SGShivshankar Gunjegaonkar
Shivshankar Gunjegaonkar
SWS.B. Wankhede
S.B. Wankhede
TST.S. Shanmugarajan
T.S. Shanmugarajan
SSS.D. Shinde
S.D. Shinde
The current investigation was carried out to screen antiarthritic potential of Methyl Jasmonate (MJ) against lipopolysaccharide (LPS) induced arthritis. Cartilage damage was induced in experimental animals by intraplantar administration of LPS (1 mg/kg) and antiarthritic effect of MJ was screened in two doses of MJ-1 (20 mg/kg), MJ-2 (40 mg/kg) by intraperitoneally administration. Indomethacin (30 mg/kg p.o.) was used as standard drug. The severity of arthritis was evaluated by assessing arthritis score, secondary lesions, motility test, stair climbing ability, and dorsal flexion pain score method. The estimation of blood cytokine tumor necrosis factor- aplha (TNF-α),interleukine (IL-2 and IL-6) and thymus/spleen index was carried out to access the severity of inflammation. Estimation of hepaticenzymatic antioxidant activity superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPx)and radiological examination was carried out on 28th day. Results indicated that MJ showed significant reduction in severity of arthritis by decreasing arthritis score, secondary lesions where as significant increase in motility, climbing ability and flexion pain score was observed. Significant decreased in blood cytokine viz. TNF-α, IL-2, IL-6 andthymus/spleen index was observed in MJ treated animals in dose dependent manner. MJ treated animals showed significant increased and restoration of hepatic antioxidant enzymatic activityof SOD, CAT, GSH, GPx where asradiological examination indicates protective effect on joint structure as compared to LPS treated rats. These current studies conclude that MJ has protective role in arthritis.

17 November 2022 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
SGShivshankar Gunjegaonkar
Shivshankar Gunjegaonkar
VKV.R. Khakal
V.R. Khakal
AJA.A. Joshi
A.A. Joshi
SNS.L. Nargund
S.L. Nargund
SSS.D. Shinde
S.D. Shinde
NKN.S. Khan
N.S. Khan
Ayurdvedic derived medicines are most promising and effective in the treatment of several cardiovascular diseases. Cocculus hirsutus (CH) has been reported for broad spectrum of activities like anticancer, antidiabetic, antioxidant, cardiotonic and hypotensive etc. The present study aimed to find the cardio-protective effect of CH in experimental hypertension in rats. For acute renal hypertension, CH animals were pre-treated with CH-1 (250 mg/kg) and CH-2 (500 mg/kg) p. o. for 14 days. On the 15th day, hypertension was induced by renal occlusion and the mean arterial blood pressure (MABP) was recorded. For CAL pretreatment of CH-1 and CH-2 was given for 7 days on the 8th day animals were operated on for ligation. The MABP and the time of onset of ventricular tachycardia (VT), premature ventricular systole (PVS) were recorded. For induction of hypercholesterolemia, animals were fed with a high cholesterol diet (CD) with CH-1 and CH-2 for 21 days. The antioxidant potential of CH was done using the assay of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), and glutathione peroxidase (GPx). CH treatment significantly decreases the MABP, the onset of VT and PVS. The histology show intact cardiac muscle with minimum necrosis and inflammation. CH treatment shows significant decrease in cholesterol, triglycerides, and glucose while HDL levels are significantly increased. The aortic section of CH-treated animals shows the intact layers of the artery, normal thickness and restoration of antioxidant enzymatic activity. The study shows significant cardio protective effect of CH in experimental animals.


22 July 2026 in Journal of Pharmacology and Pharmacotherapeutics
Verified
Journal Article
Open access
MNMaralikar Mukta Nitin
Maralikar Mukta Nitin
MBMada Shrija Bhaskar
Mada Shrija Bhaskar
LALangote Prathmesh Ashok
Langote Prathmesh Ashok
SUShinde Mahesh Uttamrao
Shinde Mahesh Uttamrao
TSTour Nagesh Shivaji
Tour Nagesh Shivaji
SGShivshankar Gunjegaonkar
Shivshankar Gunjegaonkar
Background: Drug Utilisation Review (DUR) and the Medication Regimen Complexity Index (MRCI) are emerging tools to optimise prescribing, minimise regimen burden and improve outcomes in gynaecological pharmacotherapy. However, their application in routine clinical practice remains underexplored. Purpose: To evaluate medication utilisation patterns and regimen complexity in gynaecological patients using DUR and MRCI, and to identify the impact of complexity on adherence and clinical outcomes. Materials and Methods: A prospective observational study was conducted on 300 gynaecological patients attending the gynaecology department of a government hospital in Dharashiv. Demographic, clinical and prescribing data were collected and analysed using Statistical Package for Social Sciences. Descriptive statistics were presented as mean ± SD, percentage and 95% confidence intervals (CIs). One-way analysis of variance was used for group comparisons, while chi-square ( χ ²) tests were used to assess associations between MRCI and clinical parameters. Results: The majority of patients were in the 26–30-year age group (19.33%, p < .0001*), and 28.3% were overweight/obese ( p < .0001*). Anaemia (Hb < 11 g/dL) was observed in 49.16% of cases ( p < .05*). The most frequently prescribed drugs included Ceftriaxone (84.3%, p < .05*), Pantoprazole (77.6%, p < .05*) and Ondansetron (65%, p < .05*), with high rates of empirical antibiotic use. MRCI analysis revealed that 50.3% of patients had high regimen complexity (>20, p < .05*), 33.6% moderate (11–20, p < .05*) and 16% low (≤10, p < .05*). Significant associations were noted between MRCI and anaemia ( χ ² = 10.62, p = .0049*), and between MRCI and polypharmacy ( χ ² = 45.13, p < .001*), while no association was observed with place of residence ( p = .81, ns). Conclusion: This study demonstrated a high prevalence of anaemia, empirical antibiotic prescribing and complex regimens in gynaecological patients. DUR and MRCI proved useful in identifying inappropriate prescribing and quantifying regimen complexity. Incorporating pharmacist-led counselling, multidisciplinary care and AI-driven DUR systems may help improve adherence, reduce polypharmacy and optimise pharmacotherapy in gynaecological practice.